Liraglutide's efficacy and safety investigated as add-on for Type 2 Diabetes with moderate renal impairment

Type 2 Diabetes (T2D) is a chronic metabolic disorder often complicated by renal impairment, which limits treatment options. Many existing glucose-lowering medications require dose adjustments or are contraindicated in patients with reduced kidney function, posing a significant clinical challenge. Liraglutide, a GLP-1 receptor agonist, has demonstrated cardiovascular and renal benefits in T2D patients without renal impairment. This study addresses the critical need for safe and effective add-on therapies for T2D patients specifically with moderate renal impairment.

This trial is a placebo-controlled study investigating liraglutide as an add-on therapy. Subjects with Type 2 Diabetes and moderate renal impairment will receive liraglutide or placebo in addition to their stable oral antidiabetic drugs (OADs) and/or insulin regimen. The study aims to assess both efficacy and safety. Specific dosing, frequency, duration, and primary endpoints are not detailed in the provided abstract.

This abstract describes the design and purpose of the trial, but does not present any findings or results. Therefore, no specific efficacy or safety data, statistical outcomes, or quantitative measures from the study are available in this record. The trial's objective is to compare liraglutide against placebo in Type 2 Diabetes patients with moderate renal impairment, focusing on both glucose control and adverse events. Further details regarding the study's outcomes would be available upon completion and publication of the full results.